EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Pertuzumab
Related studies linked through entity extraction aliases.
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
- Status
- RECRUITING
- Phase
- PHASE3
Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study
- Status
- UNKNOWN
- Phase
- NA
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
A Study for the Adjuvant Treatment of Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE4
A Study for the Neoadjuvant Treatment of Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE4
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
- Status
- TERMINATED
- Phase
- PHASE1
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Status
- RECRUITING
- Phase
- PHASE2
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
SMMART Adaptive Clinical Treatment (ACT) Trial
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
- Status
- TERMINATED
- Phase
- PHASE2